With Overstretched FDA, Companies Advised To Conduct Their Own Foreign Inspections – Former FDA Chief Counsel
This article was originally published in PharmAsia News
Executive Summary
FDA's failure to inspect a Chinese API manufacturer that may be linked to the heparin safety issue will "drive home" to the pharmaceutical industry the need to ensure the safety of the ingredients in drug products, according to an industry expert
You may also be interested in...
HHS Secretary Leavitt Calls For “Explicit Extraterritorial Jurisdiction” For U.S. FDA
U.S. Health and Human Services Secretary Michael Leavitt requested Congress in a Feb. 22 letter to grant FDA "explicit extraterritorial jurisdiction" to investigate manufacturers whose products are subject to the Federal Food, Drug, and Cosmetic Act
HHS Secretary Leavitt Calls For “Explicit Extraterritorial Jurisdiction” For U.S. FDA
U.S. Health and Human Services Secretary Michael Leavitt requested Congress in a Feb. 22 letter to grant FDA "explicit extraterritorial jurisdiction" to investigate manufacturers whose products are subject to the Federal Food, Drug, and Cosmetic Act
Congressional Leaders To Consider “Emergency Legislation” In Wake Of Heparin Safety Scare
Congressional leaders have ratcheted up the heat on U.S. FDA and Baxter Healthcare over their handling of the heparin safety scare, alleging that the agency has abandoned its policy to conduct preapproval inspections of API suppliers and saying they would consider introducing "emergency legislation" to mandate such inspections